Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing Phase 2a clinical trial...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced initial clinical data from cohorts in its ongoing Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor...
– 83% overall response rate, with evidence of deepening of response over time – – Median duration of response not reached; 12-month duration of response rate of 76% – – Statistically significant improvements in patient-reported disease...
Researchers plan to enroll approximately 420 couples in clinical trial. A clinical trial funded by the National Institutes of Health will evaluate a male contraceptive gel for its ability to prevent pregnancy. The gel formulation was developed by the Population...
U.S. contract research organization market accounted for 86.7% revenue share of North America in 2017 and is expected to grow considerably during the forecast year owing to growing patient concern pertaining to safety and efficacy of drugs increases demand for CRO...
Email
Text